BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35220934)

  • 21. Combined inhibition of Bcl-2 and NFκB synergistically induces cell death in cutaneous T-cell lymphoma.
    Froehlich TC; Müller-Decker K; Braun JD; Albrecht T; Schroeder A; Gülow K; Goerdt S; Krammer PH; Nicolay JP
    Blood; 2019 Aug; 134(5):445-455. PubMed ID: 31167801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma.
    Cao M; Lai P; Liu X; Liu F; Qin Y; Tu P; Wang Y
    Front Immunol; 2023; 14():1282996. PubMed ID: 38223508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
    Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway.
    Ren S; Xing Y; Wang C; Jiang F; Liu G; Li Z; Jiang T; Zhu Y; Piao D
    Int J Biochem Cell Biol; 2020 Aug; 125():105777. PubMed ID: 32504672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-cell leukemia cells.
    Yang J; Ikezoe T; Nishioka C; Furihata M; Yokoyama A
    Mol Cancer Ther; 2010 Dec; 9(12):3386-95. PubMed ID: 21159615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.
    Matsuda Y; Ikeda S; Abe F; Takahashi Y; Kitadate A; Takahashi N; Wakui H; Tagawa H
    Cancer Sci; 2022 Apr; 113(4):1208-1219. PubMed ID: 35133054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma.
    Xu L; Qin Y; Liu M; Jiao J; Tu D; Zhang M; Yan D; Song X; Sun C; Zhu F; Wang X; Sang W; Xu K
    Anticancer Agents Med Chem; 2022; 22(8):1530-1540. PubMed ID: 34503423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. JAK2 regulation by licochalcone H inhibits the cell growth and induces apoptosis in oral squamous cell carcinoma.
    Oh HN; Oh KB; Lee MH; Seo JH; Kim E; Yoon G; Cho SS; Cho YS; Choi HW; Chae JI; Shim JH
    Phytomedicine; 2019 Jan; 52():60-69. PubMed ID: 30599913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
    Zhang C; Hazarika P; Ni X; Weidner DA; Duvic M
    Clin Cancer Res; 2002 May; 8(5):1234-40. PubMed ID: 12006543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3.
    Zhang T; Jiang B; Zou ST; Liu F; Hua D
    World J Gastroenterol; 2015 Feb; 21(6):1804-13. PubMed ID: 25684945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand.
    Braun FK; Al-Yacoub N; Plötz M; Möbs M; Sterry W; Eberle J
    J Invest Dermatol; 2012 Feb; 132(2):429-39. PubMed ID: 22011910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis.
    Chou CF; Hsieh YH; Grubbs CJ; Atigadda VR; Mobley JA; Dummer R; Muccio DD; Eto I; Elmets CA; Garvey WT; Chang PL
    J Dermatol Sci; 2018 Jun; 90(3):343-356. PubMed ID: 29599065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
    Tantawy MA; El-Sherbeeny NA; Helmi N; Alazragi R; Salem N; Elaidy SM
    Mol Cell Biochem; 2020 Jun; 469(1-2):143-157. PubMed ID: 32356241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells.
    Zhang CL; Kamarashev J; Qin JZ; Burg G; Dummer R; Döbbeling U
    J Pathol; 2003 Jun; 200(2):249-54. PubMed ID: 12754746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A natural compound derivative P-13 inhibits STAT3 signaling by covalently inhibiting Janus kinase 2.
    Huang H; Niu J; Wang F; Hu L; Yu Q
    Invest New Drugs; 2019 Jun; 37(3):452-460. PubMed ID: 30073465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy.
    Berger CL; Edelson R
    Curr Cancer Drug Targets; 2004 Nov; 4(7):609-19. PubMed ID: 15578918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
    Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
    Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.
    Yumeen S; Mirza FN; Lewis JM; King ALO; Kim SR; Carlson KR; Umlauf SR; Surovtseva YV; Foss FM; Girardi M
    Blood Adv; 2020 May; 4(10):2213-2226. PubMed ID: 32437546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.